Format

Send to:

Choose Destination
See comment in PubMed Commons below
Surg Today. 2013 Jun;43(6):654-60. doi: 10.1007/s00595-012-0437-9. Epub 2012 Nov 29.

High expression of cancer stem cell markers in cholangiolocellular carcinoma.

Author information

  • 1Department of Surgery, Institute of Health Biosciences, The University of Tokushima Graduate School, 3-18-15 Kuramoto-cho, Tokushima 770-8503, Japan.

Abstract

PURPOSE:

Cholangiolocellular carcinoma (CLC) is an extremely rare malignant liver tumor. It is thought to originate from the ductules and/or canals of Hering, where hepatic stem cells (HpSC) are located, but there are few reports on cancer stem cell markers in CLC. Thus, we evaluated the significance of cancer stem cell markers, including CD133, CD44, and EpCAM, in CLC.

METHODS:

The subjects of this study were three patients with CLC and one patient with an intermediate type of combined hepatocellular cholangiocarcinoma (CHC). The cancer cell markers, CK7, CK19, and EMA, were evaluated immunohistochemically.

RESULTS:

Histological examination of the CLC revealed morphologically cholangiolar features and immunohistochemical examination revealed positivity for CD133, CD44, and EpCAM. On the other hand, in the intermediate type of CHC, only CD44 was positive, whereas CD133 and EpCAM were negative.

CONCLUSION:

CLC may have stronger features derived from HpSCs than an intermediate type of CHC.

PMID:
23192764
[PubMed - indexed for MEDLINE]
PMCID:
PMC3651534
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer Icon for PubMed Central
    Loading ...
    Write to the Help Desk